A federal judge on Thursday declined to block the bankruptcy sale of genetic testing company 23andMe to its co-founder Anne ...

Long-term treatment with ixekizumab does not increase the incidence of malignant neoplasms in patients with psoriasis, PsA, ...

Jeffrey Hsi, a longtime physics teacher at South High School in the Valley Stream Central High School District, has been ...

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

A court battle between two of the nation’s largest biotechs is testing the legal limits of how far drugmakers can go in using ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 best debt-free stocks to invest in right now. The company ...

This LSPN panel features experts from Maiwald, Regeneron, Vertex Pharmaceuticals, and Taylor Wessing discussing the impact of ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the most undervalued large cap stocks to buy according to analysts. On ...

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...

When it comes to groundbreaking biotech advancements, Eric Faw Intellia is a name you might wanna keep an eye on. This ...

For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer ...